patents.google.com

CN105030984B - A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication - Google Patents

  • ️Tue Dec 04 2018
A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication Download PDF

Info

Publication number
CN105030984B
CN105030984B CN201510452519.8A CN201510452519A CN105030984B CN 105030984 B CN105030984 B CN 105030984B CN 201510452519 A CN201510452519 A CN 201510452519A CN 105030984 B CN105030984 B CN 105030984B Authority
CN
China
Prior art keywords
oral liquid
lychee
litchi
core
parts
Prior art date
2015-07-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510452519.8A
Other languages
Chinese (zh)
Other versions
CN105030984A (en
Inventor
满淑丽
路福平
马江
王春霞
高文远
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Gaoguan Food Co ltd
Original Assignee
Tianjin University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2015-07-28
Filing date
2015-07-28
Publication date
2018-12-04
2015-07-28 Application filed by Tianjin University of Science and Technology filed Critical Tianjin University of Science and Technology
2015-07-28 Priority to CN201510452519.8A priority Critical patent/CN105030984B/en
2015-11-11 Publication of CN105030984A publication Critical patent/CN105030984A/en
2018-12-04 Application granted granted Critical
2018-12-04 Publication of CN105030984B publication Critical patent/CN105030984B/en
Status Active legal-status Critical Current
2035-07-28 Anticipated expiration legal-status Critical

Links

  • 241001629511 Litchi Species 0.000 title claims abstract description 61
  • 239000007788 liquid Substances 0.000 title claims abstract description 45
  • 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 28
  • 206010012655 Diabetic complications Diseases 0.000 title claims abstract description 28
  • 230000002218 hypoglycaemic effect Effects 0.000 title claims description 25
  • 230000036541 health Effects 0.000 title claims description 17
  • 238000002360 preparation method Methods 0.000 title claims description 11
  • JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 title 1
  • 210000000582 semen Anatomy 0.000 title 1
  • LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 89
  • 244000183278 Nephelium litchi Species 0.000 claims abstract description 40
  • 235000015742 Nephelium litchi Nutrition 0.000 claims abstract description 40
  • 210000004369 blood Anatomy 0.000 claims abstract description 38
  • 239000008280 blood Substances 0.000 claims abstract description 38
  • 230000000694 effects Effects 0.000 claims abstract description 28
  • 239000000284 extract Substances 0.000 claims abstract description 24
  • 230000001105 regulatory effect Effects 0.000 claims abstract description 15
  • XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
  • UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 9
  • TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 9
  • HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 9
  • 229940013618 stevioside Drugs 0.000 claims abstract description 9
  • OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 9
  • 235000019202 steviosides Nutrition 0.000 claims abstract description 9
  • 235000010447 xylitol Nutrition 0.000 claims abstract description 9
  • HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 9
  • 239000000811 xylitol Substances 0.000 claims abstract description 9
  • 229960002675 xylitol Drugs 0.000 claims abstract description 9
  • 235000002639 sodium chloride Nutrition 0.000 claims abstract description 7
  • BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims abstract description 6
  • 235000010199 sorbic acid Nutrition 0.000 claims abstract description 6
  • 229940075582 sorbic acid Drugs 0.000 claims abstract description 6
  • 239000004334 sorbic acid Substances 0.000 claims abstract description 6
  • 239000006228 supernatant Substances 0.000 claims description 16
  • 239000002994 raw material Substances 0.000 claims description 15
  • 238000000605 extraction Methods 0.000 claims description 12
  • 238000001914 filtration Methods 0.000 claims description 12
  • 239000002244 precipitate Substances 0.000 claims description 10
  • 239000000203 mixture Substances 0.000 claims description 8
  • 238000010992 reflux Methods 0.000 claims description 8
  • 238000002156 mixing Methods 0.000 claims description 6
  • 150000003839 salts Chemical class 0.000 claims description 5
  • 239000002904 solvent Substances 0.000 claims description 5
  • 238000003756 stirring Methods 0.000 claims description 5
  • 239000000469 ethanolic extract Substances 0.000 claims description 4
  • 238000005119 centrifugation Methods 0.000 claims description 2
  • 238000009924 canning Methods 0.000 claims 1
  • 238000007789 sealing Methods 0.000 claims 1
  • 229930182490 saponin Natural products 0.000 abstract description 8
  • 150000007949 saponins Chemical class 0.000 abstract description 8
  • 235000017709 saponins Nutrition 0.000 abstract description 8
  • 239000004615 ingredient Substances 0.000 abstract description 7
  • 208000024891 symptom Diseases 0.000 abstract description 7
  • REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract description 6
  • VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 abstract description 6
  • 150000002632 lipids Chemical class 0.000 abstract description 6
  • FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 5
  • 238000004458 analytical method Methods 0.000 abstract description 4
  • 235000014113 dietary fatty acids Nutrition 0.000 abstract description 4
  • 229930195729 fatty acid Natural products 0.000 abstract description 4
  • 239000000194 fatty acid Substances 0.000 abstract description 4
  • 150000004665 fatty acids Chemical class 0.000 abstract description 4
  • 229930003935 flavonoid Natural products 0.000 abstract description 4
  • 150000002215 flavonoids Chemical class 0.000 abstract description 4
  • 235000017173 flavonoids Nutrition 0.000 abstract description 4
  • IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract description 4
  • 230000006872 improvement Effects 0.000 abstract description 4
  • JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 abstract description 3
  • 208000004880 Polyuria Diseases 0.000 abstract description 3
  • ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract description 3
  • HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract description 3
  • 229940076810 beta sitosterol Drugs 0.000 abstract description 3
  • LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 abstract description 3
  • NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 abstract description 3
  • -1 carotin Chemical compound 0.000 abstract description 3
  • 230000035622 drinking Effects 0.000 abstract description 3
  • IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 abstract description 3
  • MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 3
  • 206010036067 polydipsia Diseases 0.000 abstract description 3
  • 235000005875 quercetin Nutrition 0.000 abstract description 3
  • 229960001285 quercetin Drugs 0.000 abstract description 3
  • FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 abstract description 3
  • ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 abstract description 3
  • IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 abstract description 3
  • 235000005493 rutin Nutrition 0.000 abstract description 3
  • 229960004555 rutoside Drugs 0.000 abstract description 3
  • KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 abstract description 3
  • 229950005143 sitosterol Drugs 0.000 abstract description 3
  • 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 abstract description 3
  • 206010020710 Hyperphagia Diseases 0.000 abstract description 2
  • 235000021314 Palmitic acid Nutrition 0.000 abstract description 2
  • 206010016256 fatigue Diseases 0.000 abstract description 2
  • WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 abstract description 2
  • 208000022530 polyphagia Diseases 0.000 abstract description 2
  • 239000011780 sodium chloride Substances 0.000 abstract description 2
  • 206010012601 diabetes mellitus Diseases 0.000 description 22
  • 241000700159 Rattus Species 0.000 description 18
  • 238000000034 method Methods 0.000 description 16
  • 208000001072 type 2 diabetes mellitus Diseases 0.000 description 13
  • 239000000047 product Substances 0.000 description 11
  • 206010022489 Insulin Resistance Diseases 0.000 description 9
  • 239000003814 drug Substances 0.000 description 9
  • HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
  • 239000008187 granular material Substances 0.000 description 6
  • 238000004519 manufacturing process Methods 0.000 description 6
  • 239000000843 powder Substances 0.000 description 6
  • 238000001556 precipitation Methods 0.000 description 6
  • 230000008569 process Effects 0.000 description 6
  • WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
  • 229940079593 drug Drugs 0.000 description 5
  • 239000008103 glucose Substances 0.000 description 5
  • 239000000463 material Substances 0.000 description 5
  • 238000012360 testing method Methods 0.000 description 5
  • 210000002700 urine Anatomy 0.000 description 5
  • 238000003809 water extraction Methods 0.000 description 5
  • 240000000249 Morus alba Species 0.000 description 4
  • 235000008708 Morus alba Nutrition 0.000 description 4
  • 239000004480 active ingredient Substances 0.000 description 4
  • 239000006227 byproduct Substances 0.000 description 4
  • 235000012000 cholesterol Nutrition 0.000 description 4
  • 150000001875 compounds Chemical class 0.000 description 4
  • 235000005911 diet Nutrition 0.000 description 4
  • 230000037213 diet Effects 0.000 description 4
  • 238000011049 filling Methods 0.000 description 4
  • NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
  • 239000000243 solution Substances 0.000 description 4
  • 208000002193 Pain Diseases 0.000 description 3
  • 229930013930 alkaloid Natural products 0.000 description 3
  • KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
  • 239000003651 drinking water Substances 0.000 description 3
  • 235000020188 drinking water Nutrition 0.000 description 3
  • 239000012535 impurity Substances 0.000 description 3
  • 238000012545 processing Methods 0.000 description 3
  • ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
  • 238000011282 treatment Methods 0.000 description 3
  • UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
  • 108010023302 HDL Cholesterol Proteins 0.000 description 2
  • 102000004877 Insulin Human genes 0.000 description 2
  • 108090001061 Insulin Proteins 0.000 description 2
  • 241001465754 Metazoa Species 0.000 description 2
  • ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
  • 230000002411 adverse Effects 0.000 description 2
  • 150000003797 alkaloid derivatives Chemical class 0.000 description 2
  • HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
  • 238000001514 detection method Methods 0.000 description 2
  • 238000003304 gavage Methods 0.000 description 2
  • 150000004676 glycans Chemical class 0.000 description 2
  • JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
  • 201000001421 hyperglycemia Diseases 0.000 description 2
  • 238000002347 injection Methods 0.000 description 2
  • 239000007924 injection Substances 0.000 description 2
  • 229940125396 insulin Drugs 0.000 description 2
  • 230000007774 longterm Effects 0.000 description 2
  • 238000012423 maintenance Methods 0.000 description 2
  • 239000002245 particle Substances 0.000 description 2
  • 229920001282 polysaccharide Polymers 0.000 description 2
  • 239000005017 polysaccharide Substances 0.000 description 2
  • 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
  • 238000011160 research Methods 0.000 description 2
  • 210000002966 serum Anatomy 0.000 description 2
  • 230000001954 sterilising effect Effects 0.000 description 2
  • 238000004659 sterilization and disinfection Methods 0.000 description 2
  • 229960001052 streptozocin Drugs 0.000 description 2
  • 239000000126 substance Substances 0.000 description 2
  • MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
  • 208000024172 Cardiovascular disease Diseases 0.000 description 1
  • 208000017701 Endocrine disease Diseases 0.000 description 1
  • 108010010234 HDL Lipoproteins Proteins 0.000 description 1
  • 102000015779 HDL Lipoproteins Human genes 0.000 description 1
  • HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
  • 241000700721 Hepatitis B virus Species 0.000 description 1
  • 206010049077 Hernia pain Diseases 0.000 description 1
  • 208000031226 Hyperlipidaemia Diseases 0.000 description 1
  • 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
  • 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
  • 108010007622 LDL Lipoproteins Proteins 0.000 description 1
  • 102000007330 LDL Lipoproteins Human genes 0.000 description 1
  • 102000016267 Leptin Human genes 0.000 description 1
  • 108010092277 Leptin Proteins 0.000 description 1
  • 208000017170 Lipid metabolism disease Diseases 0.000 description 1
  • 206010067125 Liver injury Diseases 0.000 description 1
  • 206010028980 Neoplasm Diseases 0.000 description 1
  • 229930006000 Sucrose Natural products 0.000 description 1
  • CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
  • 206010043345 Testicular pain Diseases 0.000 description 1
  • 206010043354 Testicular swelling Diseases 0.000 description 1
  • 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
  • 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
  • 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
  • 210000001015 abdomen Anatomy 0.000 description 1
  • 239000012675 alcoholic extract Substances 0.000 description 1
  • 230000003064 anti-oxidating effect Effects 0.000 description 1
  • 230000009286 beneficial effect Effects 0.000 description 1
  • 230000008901 benefit Effects 0.000 description 1
  • WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
  • 230000033228 biological regulation Effects 0.000 description 1
  • 230000037396 body weight Effects 0.000 description 1
  • 230000000295 complement effect Effects 0.000 description 1
  • 239000002131 composite material Substances 0.000 description 1
  • 235000009508 confectionery Nutrition 0.000 description 1
  • 238000007796 conventional method Methods 0.000 description 1
  • 230000007812 deficiency Effects 0.000 description 1
  • 238000011697 diabetes animal model Methods 0.000 description 1
  • 230000000857 drug effect Effects 0.000 description 1
  • 230000002526 effect on cardiovascular system Effects 0.000 description 1
  • 208000030172 endocrine system disease Diseases 0.000 description 1
  • 230000007613 environmental effect Effects 0.000 description 1
  • 238000002474 experimental method Methods 0.000 description 1
  • 239000000945 filler Substances 0.000 description 1
  • 239000000796 flavoring agent Substances 0.000 description 1
  • LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
  • 235000013305 food Nutrition 0.000 description 1
  • 235000013355 food flavoring agent Nutrition 0.000 description 1
  • 230000037406 food intake Effects 0.000 description 1
  • 235000012631 food intake Nutrition 0.000 description 1
  • 230000002068 genetic effect Effects 0.000 description 1
  • 230000004110 gluconeogenesis Effects 0.000 description 1
  • 208000018914 glucose metabolism disease Diseases 0.000 description 1
  • 238000007446 glucose tolerance test Methods 0.000 description 1
  • 235000013402 health food Nutrition 0.000 description 1
  • 229920000669 heparin Polymers 0.000 description 1
  • 229960002897 heparin Drugs 0.000 description 1
  • 235000009200 high fat diet Nutrition 0.000 description 1
  • 235000021070 high sugar diet Nutrition 0.000 description 1
  • 235000012907 honey Nutrition 0.000 description 1
  • 206010020488 hydrocele Diseases 0.000 description 1
  • 229960000890 hydrocortisone Drugs 0.000 description 1
  • 238000011629 hyperlipidemia animal model Methods 0.000 description 1
  • 238000001727 in vivo Methods 0.000 description 1
  • 230000002401 inhibitory effect Effects 0.000 description 1
  • 230000005764 inhibitory process Effects 0.000 description 1
  • 238000007689 inspection Methods 0.000 description 1
  • 238000002386 leaching Methods 0.000 description 1
  • NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
  • 229940039781 leptin Drugs 0.000 description 1
  • 230000000670 limiting effect Effects 0.000 description 1
  • 230000003859 lipid peroxidation Effects 0.000 description 1
  • 238000011866 long-term treatment Methods 0.000 description 1
  • 239000002398 materia medica Substances 0.000 description 1
  • 230000007721 medicinal effect Effects 0.000 description 1
  • 238000010172 mouse model Methods 0.000 description 1
  • 239000002777 nucleoside Substances 0.000 description 1
  • 150000003833 nucleoside derivatives Chemical class 0.000 description 1
  • 235000015097 nutrients Nutrition 0.000 description 1
  • 238000007410 oral glucose tolerance test Methods 0.000 description 1
  • 229940097411 palm acid Drugs 0.000 description 1
  • 210000000496 pancreas Anatomy 0.000 description 1
  • 239000000546 pharmaceutical excipient Substances 0.000 description 1
  • 230000001766 physiological effect Effects 0.000 description 1
  • 239000006187 pill Substances 0.000 description 1
  • 230000003449 preventive effect Effects 0.000 description 1
  • 230000001737 promoting effect Effects 0.000 description 1
  • 150000003254 radicals Chemical class 0.000 description 1
  • 238000011552 rat model Methods 0.000 description 1
  • 230000002829 reductive effect Effects 0.000 description 1
  • 230000035945 sensitivity Effects 0.000 description 1
  • 238000009366 sericulture Methods 0.000 description 1
  • 238000001228 spectrum Methods 0.000 description 1
  • 230000002195 synergetic effect Effects 0.000 description 1
  • 230000001225 therapeutic effect Effects 0.000 description 1
  • DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
  • 210000003462 vein Anatomy 0.000 description 1

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明涉及一种具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液，其组成成分及重量份数如下：荔枝核醇提液40～72份；山梨酸0.02～0.05份；食盐0.01～0.5份；木糖醇8～20份；甜菊糖0.1～0.3份；水10～40份。本发明口服液具有降糖、调脂及缓解糖尿病并发症的功效，富集了荔枝核中黄酮、皂苷、脂肪酸类成分，经UPLC‑MS分析，鉴定出包括棕榈酸、花生酸、乔松素‑7‑新橙皮糖苷、乔松素‑7‑芸香糖苷、芦丁、胡萝卜苷、β‑谷甾醇，槲皮素等成分，饮后具有调节血糖，降低血脂，对多饮、多食、多尿、乏力等主要临床症状有一定的改善作用。The invention relates to a health-care oral liquid of lychee kernels capable of lowering blood sugar, regulating lipids and alleviating diabetic complications. The components and parts by weight are as follows: 40-72 parts of lychee kernel alcohol extract; 0.02-0.05 parts of sorbic acid; table salt 0.01-0.5 parts; xylitol 8-20 parts; stevioside 0.1-0.3 parts; water 10-40 parts. The oral liquid of the present invention has the effects of lowering blood sugar, regulating fat and alleviating diabetic complications, and enriches the flavonoids, saponins, and fatty acids in litchi kernels, and through UPLC-MS analysis, it is identified that the ingredients include palmitic acid, arachidic acid, and chopinenin-7 ‑Neohesperidoside, jocetin‑7‑rutinoside, rutin, carotin, β‑sitosterol, quercetin and other ingredients can regulate blood sugar and lower blood lipids after drinking, and are effective for polydipsia, polyphagia, polyuria, and fatigue and other main clinical symptoms have a certain improvement effect.

Description

一种具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服 液及制备方法A health-care oral administration of lychee kernels capable of lowering blood sugar, regulating fat and alleviating complications of diabetes liquid and preparation method

技术领域technical field

本发明属于保健品技术领域，尤其是一种以荔枝加工后的副产品荔枝核为原料加工制作的具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液及制备方法。The invention belongs to the technical field of health care products, in particular to a litchi kernel health-care oral liquid capable of lowering blood sugar, regulating lipids and relieving diabetic complications and a preparation method thereof, which is processed and manufactured by using litchi kernels, a by-product of processed litchi, as a raw material.

背景技术Background technique

糖尿病是一种受遗传和环境因素影响的多因素内分泌疾病。现代社会，人们受生活、饮食方式的影响，糖尿病的发病率呈逐年升高的趋势，成为继心血管、肿瘤疾病以后的第三号健康杀手，而其中2型糖尿病占绝大多数。目前临床上对2型糖尿病的治疗，基本以控制或治疗并发症为主要手段。糖尿病目前尚不能治愈，除服用常规西药和注射胰岛素类药物之余还需服用“辅助降血糖”类保健食品。由于糖尿病具有难以治愈，需要长期治疗的特点，调节血糖类保健品方兴未艾，而价格是市场的决定因素，那些长期使用疗效好、安全性高、价格低、不良作用小、耐受性好的药物将成为主导产品。Diabetes is a multifactorial endocrine disease influenced by genetic and environmental factors. In modern society, affected by people's life and diet, the incidence of diabetes is increasing year by year, becoming the third health killer after cardiovascular and tumor diseases, and type 2 diabetes accounts for the vast majority. At present, the clinical treatment of type 2 diabetes basically takes the control or treatment of complications as the main means. Diabetes cannot be cured at present. In addition to taking conventional western medicine and insulin injections, it is necessary to take "assistant hypoglycemic" health food. Since diabetes is difficult to cure and requires long-term treatment, blood sugar-regulating health care products are in the ascendant, and price is the decisive factor in the market. Those long-term use drugs have good curative effect, high safety, low price, small adverse effects and good tolerance will be the leading product.

根据李时珍《本草纲目》、清代食医王孟英《随身饮食谱》记载及现代医学研究证明：荔枝全枝都有药用价值，以果肉和核(种子)入药。荔枝核味甘、微苦、涩、温，有理气、散结止痛的作用；主治疝气痛、鞘膜积液、睾丸肿痛、小腹冷痛等症。近年来，已有不少关于荔枝核中活性成分对糖尿病及其并发症的预防和治疗作用。张永明等发现，荔枝核皂苷提取物可明显抑制糖异生，抑制率可达到13.19％。姜振国进一步研究发现，荔枝核皂苷能改善Ⅱ型糖尿病大鼠胰岛素抵抗大鼠糖、脂代谢障碍，显著降低模型鼠FPG、TG、TC、FFA、leptin、TNF-α含量，降低血皮质醇及胰岛素水平，显著提高ISI值，改善其胰岛素敏感性，还加强SOD活性降低MDA含量。潘竟锵等在四氧嘧啶致高血糖、糖尿病和高脂动物模型，证实荔枝核水提物和醇提取物能降低模型动物的血清三酰甘油及胆固醇，提高高密度脂蛋白胆固醇含量和HDL-C/TC比值，说明可减弱自由基损伤和抑制脂质过氧化反应，并产生协同降糖、调脂效应。According to Li Shizhen's "Compendium of Materia Medica", Qing Dynasty food doctor Wang Mengying's "Portable Diet Spectrum" records and modern medical research prove that all litchi has medicinal value, and the pulp and core (seed) are used as medicine. Lychee kernels are sweet, slightly bitter, astringent, warm, and have the effects of regulating qi, dispelling stagnation and relieving pain; it is mainly used for hernia pain, hydrocele, testicular swelling and pain, and cold pain in the lower abdomen. In recent years, there have been many studies on the preventive and therapeutic effects of active ingredients in litchi kernels on diabetes and its complications. Zhang Yongming and others found that lychee nucleoside extract can significantly inhibit gluconeogenesis, and the inhibition rate can reach 13.19%. Jiang Zhenguo's further research found that lychee saponins can improve the glucose and lipid metabolism disorders of insulin resistance rats in type Ⅱ diabetic rats, significantly reduce the levels of FPG, TG, TC, FFA, leptin, TNF-α in model mice, and reduce blood cortisol and insulin. Level, significantly increase the ISI value, improve its insulin sensitivity, but also strengthen the SOD activity and reduce the MDA content. Pan Jingqiang et al. in alloxan-induced hyperglycemia, diabetes and hyperlipidemia animal models, confirmed that litchi kernel water extract and alcohol extract can reduce serum triacylglycerol and cholesterol in model animals, and increase high-density lipoprotein cholesterol and HDL-C /TC ratio, indicating that it can weaken free radical damage and inhibit lipid peroxidation, and produce synergistic hypoglycemic and lipid-lowering effects.

通过检索，发现如下两篇与本发明专利申请相关的专利公开文献：Through the search, the following two patent publications related to the patent application of the present invention were found:

1、一种复合荔枝核降血糖颗粒及其制备方法(CN102204985A)，公开了一种复合荔枝核降血糖颗粒，含以下重量份组分：荔枝核总皂苷粉25-80、桑叶总生物碱粉25-80、填充剂750-950、矫味剂1-5。本发明还公开了该复合荔枝核降血糖颗粒的制备方法。本发明复合荔枝核降血糖颗粒以荔枝加工过程中产生的荔枝核和蚕桑行业的副产物桑叶为主要原料，制得荔枝核总皂苷粉和桑叶总生物碱粉，加上医药学上可接受的辅料，制成颗粒剂，由于荔枝核总皂苷粉和桑叶总生物碱粉两种药材药性互补的特性，可以避免单一药材的过于寒凉或过于温燥；同时两种药材均具有降血糖功能，配合使用降血糖效果更佳；本发明复合荔枝核降血糖颗粒具有良好的降血糖效果，可用于非胰岛素依赖型糖尿病患者的辅助降血糖治疗。1. A compound litchi kernel hypoglycemic granule and its preparation method (CN102204985A), which discloses a composite litchi kernel hypoglycemic granule, containing the following components in parts by weight: litchi kernel total saponin powder 25-80, mulberry leaf total alkaloids Powder 25-80, filler 750-950, flavoring agent 1-5. The invention also discloses a preparation method of the compound litchi kernel hypoglycemic granule. The compound lychee kernel hypoglycemic granule of the present invention uses the litchi kernel produced in the litchi processing process and the by-product mulberry leaf of the sericulture industry as main raw materials to prepare litchi kernel total saponin powder and mulberry leaf total alkaloid powder, plus pharmaceutically Accepted excipients are made into granules. Due to the complementary medicinal properties of the two medicinal materials, the total saponins powder of litchi core and the total alkaloid powder of mulberry leaves, it can avoid the single medicinal material from being too cold or too warm and dry; Blood sugar function, the effect of lowering blood sugar is better when used together; the compound lychee kernel hypoglycemic granule of the present invention has good blood sugar lowering effect, and can be used for auxiliary blood sugar lowering treatment of non-insulin-dependent diabetic patients.

2、荔枝核口服液及其制造方法(CN1879743)，涉及口服液技术领域，具体是荔枝核口服液及其制造方法。本发明以荔枝加工后的副产品荔枝核为原料，通过浸提、粗滤、浓缩、调配、过滤、灌装、灭菌得到荔枝核口服液。荔枝核口服液组分含量以重量配比计荔枝核浸提液为70～80％，调配辅料木糖醇8～12％或者是白砂糖6～10％和蜂蜜1～3％，柠檬酸0.1～0.5％，食盐0.05～0.1％，余量为饮用水。该口服液呈淡黄色，无沉淀，无杂质，口味独特、营养丰富，具有行气散结、祛寒止痛之功效和降血糖、调血脂、抗氧化、抗肝损伤、抑制乙肝病毒等生理作用，对于非胰岛素依赖性糖尿病也有特殊的疗效。2. Litchi Kernel Oral Liquid and its manufacturing method (CN1879743), which relates to the technical field of oral liquids, specifically Litchi Kernel Oral Liquid and its manufacturing method. The invention uses the lychee core, a by-product of litchi processing, as a raw material, and obtains the lychee core oral liquid through leaching, coarse filtration, concentration, preparation, filtration, filling and sterilization. Litchi core oral liquid contains 70-80% litchi core extract by weight, 8-12% xylitol or 6-10% white sugar, 1-3% honey and 0.1% citric acid ～0.5%, table salt 0.05～0.1%, and the balance is drinking water. The oral liquid is light yellow, free of precipitation, free of impurities, unique in taste, and rich in nutrients. It has the effects of promoting qi and dispelling stagnation, dispelling cold and relieving pain, and has physiological effects such as lowering blood sugar, regulating blood lipids, anti-oxidation, anti-liver damage, and inhibiting hepatitis B virus. , It also has a special effect on non-insulin-dependent diabetes.

通过对比，本发明专利申请与上述专利公开文献相比，本发明专利申请采用不同梯度的乙醇回流提取和水提醇沉法相结合，在去除大颗粒杂质的同时，也去除了相当一部分多糖类物质，减少了糖尿病患者对糖类物质的摄入；提高了荔枝核中降糖调脂等有效成分的提取率；木糖醇和甜菊糖按比例搭配，不仅满足糖尿病患者对摄入糖种类的苛刻需求，而且在降低生产成本的同时，使产品口感更佳；尽量少地添加辅料，在最大程度上保证了产品中有效成分的稳定性。By comparison, compared with the above-mentioned patent publications, the patent application of the present invention uses a combination of different gradients of ethanol reflux extraction and water extraction and alcohol precipitation to remove a considerable portion of polysaccharides while removing large particles of impurities. Substances, reducing the sugar intake of diabetic patients; improving the extraction rate of effective ingredients such as hypoglycemic and lipid-lowering in lychee kernels; xylitol and stevioside are matched in proportion, which not only meets the strict requirements of diabetics on the type of sugar intake Demand, and while reducing production costs, make the product taste better; add as few auxiliary materials as possible to ensure the stability of the active ingredients in the product to the greatest extent.

发明内容Contents of the invention

本发明的目的在于克服现有技术的不足之处，提供一种以荔枝加工后的副产品荔枝核为原料加工制作的口服液及其制造方法，该口服液具有降糖、调脂及缓解糖尿病并发症的功效，饮后具有调节血糖，降低血脂，对多饮、多食、多尿、乏力等主要临床症状有一定的改善作用。The purpose of the present invention is to overcome the deficiencies of the prior art, to provide a kind of oral liquid processed and made from litchi core, a by-product of litchi processing, and its manufacturing method. It has the effect of regulating blood sugar and lowering blood lipid after drinking, and has a certain improvement effect on main clinical symptoms such as polydipsia, polyphagia, polyuria, and fatigue.

本发明解决其技术问题所采用的技术方案是：The technical solution adopted by the present invention to solve its technical problems is:

一种具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液，其组成成分及重量份数如下：A lychee core health-care oral liquid with the functions of lowering blood sugar, regulating fat and alleviating diabetic complications, the components and parts by weight are as follows:

而且，其组成成分及重量份数如下：And, its composition and parts by weight are as follows:

而且，所述口服液的食用方法及用量为：食用方法为口服，用量为1～10g(按照荔枝核原料计算)/日。Moreover, the eating method and dosage of the oral liquid are as follows: the eating method is oral administration, and the dosage is 1-10 g (calculated according to litchi core raw materials) per day.

如上所述的具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液的制备方法，步骤如下：As mentioned above, the preparation method of Litchi Kernel Health Oral Liquid with hypoglycemic, fat-regulating and alleviating diabetic complications, the steps are as follows:

将荔枝核洗净，原料破碎后，以5～8倍重量的30～95％乙醇为溶媒，回流提取1～6次，每次2小时，过100～200目筛，将获得的荔枝核提取液用3500～5000转/min的转速离心，离心15～30min后，过滤得上清，上清回收乙醇，将提取液浓缩至65℃时相对密度为1.10-1.20，加乙醇使含醇量的体积百分比达65-85％，搅拌，静置，过滤，得荔枝核醇沉物，离心除沉淀，离心条件为转速3500-5000转/min、离心15～30min，过滤后得上清液，上清液回收乙醇，将提取液浓缩至相对密度为1.20-1.30，即得荔枝核醇提液，再依次加入山梨酸、食盐、木糖醇、甜菊糖，混合，加水，水的加入量为使其终体积为原料荔枝核40-50倍的水量，充分溶解后加入至调配罐中，搅拌器充分调配混匀后过滤、灌装、封口、杀菌处理，即得具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液。Wash the lychee core, after the raw material is crushed, use 5-8 times the weight of 30-95% ethanol as a solvent, reflux extraction 1-6 times, each time for 2 hours, pass through a 100-200 mesh sieve, and extract the obtained lychee core The solution is centrifuged at a speed of 3500-5000 rpm, centrifuged for 15-30min, then filtered to obtain the supernatant, and the supernatant is recovered with ethanol, and the relative density is 1.10-1.20 when the extract is concentrated to 65°C, and ethanol is added to make the alcohol content The volume percentage reaches 65-85%, stir, stand still, and filter to obtain the litchi kernel ethanol precipitate, centrifuge to remove the precipitate, and the centrifugation conditions are 3500-5000 rpm, centrifuge for 15-30min, and obtain the supernatant after filtration. Ethanol is recovered from the clear liquid, and the extract is concentrated to a relative density of 1.20-1.30 to obtain the lychee kernel ethanol extract, and then sorbic acid, salt, xylitol, and stevioside are added in sequence, mixed, and water is added in an amount of Its final volume is 40-50 times the water volume of the raw material lychee core. After fully dissolving, it is added to the blending tank, fully blended and mixed by the agitator, and then filtered, filled, sealed, and sterilized. Lychee Kernel Health Oral Liquid for Diabetic Complications.

而且，所述过滤后的混合料液，用罐装机注入瓶中并自动封口，经过杀菌釜0.075～0.1MPa、20～30min杀菌后，冷却至62-68℃，即得到成品荔枝核口服液。Moreover, the filtered mixed material liquid is poured into the bottle with a filling machine and sealed automatically, after being sterilized by a 0.075-0.1 MPa in a sterilizer for 20-30 minutes, it is cooled to 62-68°C to obtain the finished litchi core oral liquid .

本发明取得的优点和有益效果是：Advantage and beneficial effect that the present invention obtains are:

1、本发明口服液具有降糖、调脂及缓解糖尿病并发症的功效，富集了荔枝核中黄酮、皂苷、脂肪酸类成分，经UPLC-MS分析，鉴定出包括棕榈酸、花生酸、乔松素-7-新橙皮糖苷、乔松素-7-芸香糖苷、芦丁、胡萝卜苷、β-谷甾醇，槲皮素等成分，饮后具有调节血糖，降低血脂，对多饮、多食、多尿、乏力等主要临床症状有一定的改善作用，同时，本口服液长期使用疗效好、安全性高、价格低、不良作用小、耐受性好。1. The oral liquid of the present invention has the effects of lowering blood sugar, regulating fat and alleviating diabetic complications. It is enriched in flavonoids, saponins, and fatty acids in the litchi core. Through UPLC-MS analysis, it is identified that palmitic acid, arachidic acid, and chopinenin are included. -7-Neohesperidoside, jocepin-7-rutinoside, rutin, carotin, β-sitosterol, quercetin and other ingredients can regulate blood sugar and lower blood lipids after drinking , fatigue and other main clinical symptoms have a certain improvement effect, and at the same time, the long-term use of this oral liquid has good curative effect, high safety, low price, small adverse effects and good tolerance.

2、本发明荔枝核提取方法成本较低，水提醇沉主要富集荔枝核中黄酮、皂苷、脂肪酸类成分，前期实验证明其对STZ所致的SD糖尿病大鼠模型，其生活质量、血糖指标、胰岛敏感性等均有较好作用，经体内试验证明，该口服液可显著降低2型糖尿病大鼠空腹血糖、胰岛素抵抗指数、总胆固醇、甘油三酯、饮水量、尿量等，并增加胰岛素敏感性。2. The cost of the method for extracting litchi kernels of the present invention is relatively low. Water extraction and alcohol precipitation mainly enrich flavonoids, saponins, and fatty acids in litchi kernels. Preliminary experiments have proved that it is effective for the SD diabetic rat model caused by STZ, and its quality of life, blood sugar indicators, sensitivity of islets of pancreas, etc., have good effects. The in vivo test proves that the oral liquid can significantly reduce fasting blood sugar, insulin resistance index, total cholesterol, triglyceride, drinking water volume, urine volume, etc. in type 2 diabetic rats, and Increase insulin sensitivity.

3、本发明方法改进了荔枝核有效成分的提取工艺，采用不同梯度的乙醇回流提取和水提醇沉法相结合，在去除大颗粒杂质的同时，也去除了相当一部分多糖类物质，较少了糖尿病患者对升糖物质的摄入；提高了荔枝核中降糖调脂等有效成分的提取率；木糖醇和甜菊糖按比例搭配，不仅满足糖尿病患者对摄入糖种类的苛刻需求，而且在降低生产成本的同时，使产品口感更佳；此外，甜菊糖类物质本身就有降糖功能；尽量少地添加辅料，在最大程度上保证了产品中有效成分的稳定性，以上提取工艺尽可能较少或改善提取过程中高温流程，使活性成分的损失降到最低，从而提高荔枝核的利用率，降低生产成本。3. The method of the present invention improves the extraction process of the effective components of litchi core, adopts the combination of ethanol reflux extraction of different gradients and water extraction and alcohol precipitation method, and removes a considerable part of polysaccharides while removing large particles of impurities, less It improves the intake of sugar-raising substances for diabetic patients; improves the extraction rate of effective ingredients such as hypoglycemic and lipid-lowering in lychee kernels; xylitol and stevioside are matched in proportion, which not only meets the strict needs of diabetic patients for the type of sugar intake, but also While reducing the production cost, the taste of the product is better; in addition, the stevioside itself has a hypoglycemic function; the addition of auxiliary materials as little as possible ensures the stability of the active ingredients in the product to the greatest extent. It is possible to reduce or improve the high-temperature process in the extraction process to minimize the loss of active ingredients, thereby improving the utilization rate of litchi cores and reducing production costs.

具体实施方式Detailed ways

下面结合实施例，对本发明进一步说明；下述实施例是说明性的，不是限定性的，不能以下述实施例来限定本发明的保护范围。Below in conjunction with embodiment, the present invention is further described; Following embodiment is illustrative, not limiting, can not limit protection scope of the present invention with following embodiment.

本发明中所使用的原料，如无特殊说明，均为常规的市售产品；本发明中所使用的方法，如无特殊说明，均为本领域的常规方法。The raw materials used in the present invention, unless otherwise specified, are conventional commercially available products; the methods used in the present invention, unless otherwise specified, are conventional methods in the art.

本发明中所使用的荔枝核可以为市售产品；本发明荔枝核保健口服液的制备方法工艺流程可以大致如下：The litchi core used in the present invention can be commercially available product; The preparation method technological process of litchi core health-care oral liquid of the present invention can be roughly as follows:

荔枝核→加不同比例醇回流提取→粗过滤→浓缩→水提醇沉→调配→复溶→过滤→灌装→灭菌→检验→装盒→装箱→成品。Litchi core → adding different proportions of alcohol to reflux extraction → coarse filtration → concentration → water extraction and alcohol precipitation → blending → redissolution → filtration → filling → sterilization → inspection → boxing → boxing → finished product.

实施例1Example 1

一种具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液，其组成成分及重量份数如下：A lychee core health-care oral liquid with the functions of lowering blood sugar, regulating fat and alleviating diabetic complications, the components and parts by weight are as follows:

如上所述的具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液的制备方法，步骤如下：As mentioned above, the preparation method of Litchi Kernel Health Oral Liquid with hypoglycemic, fat-regulating and alleviating diabetic complications, the steps are as follows:

将荔枝核洗净，原料破碎后，以5～8倍重量的30～95％乙醇为溶媒，回流提取1～6次(每次2小时)，过100～200目筛，将获得的荔枝核提取液用3500转/min的转速离心(15min)，过滤得上清，上清回收乙醇，将提取液浓缩至65℃时相对密度为1.10-1.20，加乙醇使含醇量的体积百分比达65％，搅拌，静置，过滤，得荔枝核醇沉物，离心除沉淀(3500转/min的转速离心15～30min，过滤)，上清液回收乙醇，将提取液浓缩至相对密度为1.20-1.30，即得荔枝核醇提液，再依次加入山梨酸、食盐、木糖醇、甜菊糖，混合，加水(使其终体积为原料荔枝核45倍水量)充分溶解后加入至调配罐中，搅拌器充分调配混匀后过滤、灌装、封口、杀菌处理，即得具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液。Wash the lychee core, after the raw material is broken, use 5-8 times the weight of 30-95% ethanol as solvent, reflux extraction 1-6 times (2 hours each time), pass through a 100-200 mesh sieve, and extract the obtained lychee core The extract is centrifuged at a speed of 3500 rpm (15 min), filtered to obtain the supernatant, and the supernatant is recovered with ethanol, and the relative density is 1.10-1.20 when the extract is concentrated to 65 °C, and ethanol is added to make the volume percentage of the alcohol content reach 65 %, stirring, standing, and filtering to obtain the litchi kernel ethanol precipitate, centrifuging to remove the precipitate (centrifuging at a speed of 3500 rpm for 15 to 30 min, filtering), reclaiming ethanol from the supernatant, and concentrating the extract to a relative density of 1.20- 1.30 to obtain the alcoholic extract of litchi kernels, then add sorbic acid, salt, xylitol, and stevioside in sequence, mix, add water (to make the final volume 45 times the amount of water of raw litchi kernels) fully dissolve, and then add it to the blending tank. The agitator is fully blended and mixed, and then filtered, filled, sealed and sterilized to obtain the Litchi Kernel Health Oral Liquid with the functions of lowering blood sugar, regulating fat and relieving diabetic complications.

实施例2Example 2

一种具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液，其组成成分及重量份数如下：A lychee core health-care oral liquid with the functions of lowering blood sugar, regulating fat and alleviating diabetic complications, the components and parts by weight are as follows:

如上所述的具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液的制备方法，步骤如下：As mentioned above, the preparation method of Litchi Kernel Health Oral Liquid with hypoglycemic, fat-regulating and alleviating diabetic complications, the steps are as follows:

将荔枝核洗净，原料破碎后，以5～8倍重量的30～95％乙醇为溶媒，回流提取1～6次(每次2小时)，过100～200目筛，将获得的荔枝核提取液用3500～5000转/min的转速离心(15～30min)，过滤得上清，上清回收乙醇，将提取液浓缩至65℃时相对密度为1.10-1.20，加乙醇使含醇量的体积百分比达65-85％，搅拌，静置，过滤，得荔枝核醇沉物，离心除沉淀(3500-5000转/min的转速离心15～30min，过滤)，上清液回收乙醇，将提取液浓缩至相对密度为1.20-1.30，即得荔枝核醇提液，再依次加入山梨酸、食盐、木糖醇、甜菊糖，混合，加水(使其终体积为原料荔枝核50倍水量)充分溶解后加入至调配罐中，搅拌器充分调配混匀后过滤、灌装、封口、杀菌处理，即得具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液。Wash the lychee core, after the raw material is broken, use 5-8 times the weight of 30-95% ethanol as solvent, reflux extraction 1-6 times (2 hours each time), pass through a 100-200 mesh sieve, and extract the obtained lychee core The extract is centrifuged at a speed of 3500-5000 rpm (15-30min), filtered to obtain the supernatant, and the supernatant is recovered with ethanol, and the relative density is 1.10-1.20 when the extract is concentrated to 65°C, and ethanol is added to reduce the alcohol content. The volume percentage reaches 65-85%, stirring, standing, and filtering to obtain the lychee kernel ethanol precipitate, centrifuging to remove the precipitate (centrifuging at a speed of 3500-5000 rpm for 15-30min, filtering), reclaiming ethanol from the supernatant, and extracting The solution is concentrated to a relative density of 1.20-1.30 to obtain the ethanol extract of lychee kernels, then sequentially add sorbic acid, salt, xylitol, stevioside, mix, add water (to make the final volume 50 times the amount of water of the raw material lychee kernels) fully After dissolving, it is added to a blending tank, fully blended by a stirrer, and then filtered, filled, sealed, and sterilized to obtain the Litchi Kernel Health Oral Liquid, which has the functions of lowering blood sugar, regulating fat, and relieving diabetic complications.

实施例3Example 3

一种具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液，其组成成分及重量份数如下：A lychee core health-care oral liquid with the functions of lowering blood sugar, regulating fat and alleviating diabetic complications, the components and parts by weight are as follows:

如上所述的具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液的制备方法，步骤如下：As mentioned above, the preparation method of Litchi Kernel Health Oral Liquid with hypoglycemic, fat-regulating and alleviating diabetic complications, the steps are as follows:

将荔枝核洗净，原料破碎后，以5～8倍重量的30～95％乙醇为溶媒，回流提取1～6次(每次2小时)，过100～200目筛，将获得的荔枝核提取液用3500～5000转/min的转速离心(15～30min)，过滤得上清，上清回收乙醇，将提取液浓缩至65℃时相对密度为1.10-1.20，加乙醇使含醇量的体积百分比达65-85％，搅拌，静置，过滤，得荔枝核醇沉物，离心除沉淀(3500-5000转/min的转速离心15～30min，过滤)，上清液回收乙醇，将提取液浓缩至相对密度为1.20-1.30，即得荔枝核醇提液，再依次加入山梨酸、食盐、木糖醇、甜菊糖，混合，加水(使其终体积为原料荔枝核40倍水量)充分溶解后加入至调配罐中，搅拌器充分调配混匀后过滤，过滤后的混合料液，用罐装机注入瓶中并自动封口，经过杀菌釜0.075～0.1MPa、20～30min杀菌后，冷却至62-68℃，即得到成品具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液。Wash the lychee core, after the raw material is broken, use 5-8 times the weight of 30-95% ethanol as solvent, reflux extraction 1-6 times (2 hours each time), pass through a 100-200 mesh sieve, and extract the obtained lychee core The extract is centrifuged at a speed of 3500-5000 rpm (15-30min), filtered to obtain the supernatant, and the supernatant is recovered with ethanol, and the relative density is 1.10-1.20 when the extract is concentrated to 65°C, and ethanol is added to reduce the alcohol content. The volume percentage reaches 65-85%, stirring, standing, and filtering to obtain the lychee kernel ethanol precipitate, centrifuging to remove the precipitate (centrifuging at a speed of 3500-5000 rpm for 15-30min, filtering), reclaiming ethanol from the supernatant, and extracting The solution is concentrated to a relative density of 1.20-1.30 to obtain the ethanol extract of lychee kernels, then sequentially add sorbic acid, salt, xylitol, stevioside, mix, add water (to make the final volume 40 times the water amount of raw material lychee kernels) fully After dissolving, add it to the blending tank, blend it fully with the agitator, and then filter it. The filtered mixture liquid is poured into the bottle with a filling machine and sealed automatically. To 62-68 ℃, the finished product Litchi Kernel Health Oral Liquid with hypoglycemic, fat-regulating and alleviating diabetic complications can be obtained.

本发明具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液的食用方法及用量为：食用方法为口服，用量为1～10g(按照荔枝核原料计算)/日。The eating method and dosage of the litchi kernel health-care oral liquid capable of lowering blood sugar, regulating fat and alleviating diabetic complications are as follows: the eating method is oral administration, and the dosage is 1-10 g (calculated according to the litchi kernel raw material) per day.

本发明的相关检测结果：Correlative detection result of the present invention:

本发明具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液经检测：水提醇沉主要富集荔枝核中黄酮、皂苷、脂肪酸类成分，经UPLC-MS分析，鉴定出包括棕榈酸、花生酸、乔松素-7-新橙皮糖苷、乔松素-7-芸香糖苷、芦丁、胡萝卜苷、β-谷甾醇，槲皮素等成分。The Litchi Kernel Health Care Oral Liquid with hypoglycemic, fat-regulating and alleviating diabetic complications has been tested: water extraction and alcohol precipitation mainly enrich the flavonoids, saponins, and fatty acids in litchi kernels, and through UPLC-MS analysis, it is identified that the ingredients including palm Acid, arachidic acid, pinocetin-7-neohesperidoside, pinocetin-7-rutinoside, rutin, carotin, β-sitosterol, quercetin and other ingredients.

本发明具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液的药效试验证明其缓解了糖尿病及其并发症等症状，具体数据如下：The drug effect test of the Litchi Kernel Health Oral Liquid, which has hypoglycemic, fat-regulating and alleviating complications of diabetes, proves that it relieves symptoms such as diabetes and its complications, and the specific data are as follows:

1二型糖尿病模型的建立1 Establishment of type 2 diabetes model

购入SD大鼠(100-130g)，普通维持料适应饲养3-5天，高糖高脂饲料喂养连续33天，喂饲4周后，尾静脉注射链脲佐菌素(Streptozotocin，STZ)，剂量：30mg/kg·BW。注射STZ72h后用安准血糖仪测定大鼠空腹(禁食12h)血糖≥11.1mmol，认为模型成功，不成模者补注一次，仍不成模者，弃去。造模完成。将成模大鼠分为给药组(分为不同剂量组)和对照组，给药组(灌胃给予不同浓度受试样品)连续给药6周，同时继续高糖高脂饲料喂养。模型对照组给予同体积生理盐水，各组给予维持料饲养。Purchase SD rats (100-130g), adapt to feeding with ordinary maintenance diet for 3-5 days, feed with high-sugar and high-fat diet for 33 consecutive days, after feeding for 4 weeks, inject streptozotocin (STZ) into tail vein , dose: 30mg/kg·BW. 72 hours after STZ injection, measure the fasting (fasting for 12 hours) blood glucose of rats ≥ 11.1mmol with the Anzhun blood glucose meter, and the model is considered successful. Modeling is complete. The model rats were divided into administration group (divided into different dosage groups) and control group, and the administration group (administrated with different concentrations of test samples) was continuously administered for 6 weeks, while continuing to be fed with high-sugar and high-fat feed. The model control group was given the same volume of normal saline, and each group was given maintenance feed.

2动物分组及给药2 Grouping and administration of animals

大鼠成模后，于次日开始给药，每日1次，每周连续给药5天，共给药6周：After the rats were modeled, the drug was administered on the next day, once a day, for 5 consecutive days a week, for a total of 6 weeks:

(1)空白组：灌服生理盐水，每只2mL；(1) Blank group: gavage with normal saline, 2 mL each;

(2)模型对照组：灌服生理盐水，每只2mL；(2) Model control group: fed with normal saline, 2 mL each;

(3)荔枝核高剂量组：按60mg/kg·bw灌服以上工艺得到的荔枝核提取物；(3) Litchi kernel high-dose group: the litchi kernel extract obtained by the above process was orally administered at 60 mg/kg bw;

(4)荔枝核中剂量组：按30mg/kg·bw灌服以上工艺得到的荔枝核提取物；(4) Medium-dose group of litchi core: the extract of litchi core obtained by the above-mentioned process is orally administered at 30 mg/kg bw;

(5)荔枝核低剂量组：按15mg/kg·bw灌服以上工艺得到的荔枝核提取物；(5) Litchi seed low-dose group: the litchi seed extract obtained by the above process was orally administered at 15 mg/kg bw;

(6)消渴丸组：按5mg/kg·bw灌服消渴丸组。(6) Xiaoke Pill group: the Xiaoke Pill group was orally administered at 5 mg/kg·bw.

3检测指标3 detection indicators

试验期间每周称量2次体重，每日测平均饮水量，平均饮食量每周测量2次，每只大鼠日尿量、尿密度、尿pH值每周测量一次，成模后每周测量大鼠空腹血糖、总胆固醇、甘油三酯、乳酸脱氢酶、高密度脂蛋白、低密度脂蛋白，给药第三周和处死前测量大鼠胰岛素抵抗指数。给药第一周和处死前进行糖耐量试验(OGTT)。每两周眼眦取血一次，加肝素抗凝，3000转/min离心15min，取上清(是常规步骤)，于-20℃保存。During the test period, the body weight was weighed twice a week, the average water intake was measured daily, and the average food intake was measured twice a week. The daily urine output, urine density, and urine pH value of each rat were measured once a week. Measure the fasting blood glucose, total cholesterol, triglyceride, lactate dehydrogenase, high-density lipoprotein, low-density lipoprotein of the rats, and measure the insulin resistance index of the rats in the third week of administration and before sacrifice. Glucose tolerance test (OGTT) was performed in the first week of administration and before sacrifice. Blood was collected from the canthus every two weeks, anticoagulated with heparin, centrifuged at 3000 rpm for 15 min, and the supernatant was taken (a routine procedure) and stored at -20°C.

4试验结果4 test results

本发明具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液对二型糖尿病大鼠的生活习性及血清中各项指标的影响如下：The present invention has hypoglycemic, lipid-lowering and relieving diabetic complication health-care oral liquid of lychee core, and the influence of each index in the living habit of type II diabetic rat and serum is as follows:

表1本发明具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液对二型糖尿病大鼠一般Table 1 The present invention has hypoglycemic, lipid-lowering and alleviates the Litchi Kernel health-care oral liquid of diabetic complication to type 2 diabetic rat normal

指标的分析表Analysis table of indicators

注：不同字母代表二组间具有显著性差异，p<0.05。Note: Different letters represent significant differences between the two groups, p<0.05.

模型组同正常组相比，多饮、多尿属于糖尿病大鼠的主要症状。本发明灌胃6周后，高、中、低剂量组、消渴丸组同模型组相比，饮水量和尿量均有明显的降低，其中以高剂量组改善饮水的效果最佳，在表中高、中药剂量下作用相当于阳性药消渴丸的作用效果；但四组药物对糖尿病大鼠的饮食量无明显作用。Compared with the normal group, polydipsia and polyuria were the main symptoms of diabetic rats in the model group. After gavage of the present invention for 6 weeks, compared with the model group, the high, middle and low dose groups and the Xiaoke Pill group had significantly reduced water intake and urine output, among which the effect of improving drinking water was the best in the high dose group. In the table, the effects of high and traditional Chinese medicine doses are equivalent to those of the positive medicine Xiaoke Pills; but the four groups of medicines have no obvious effect on the diet of diabetic rats.

表2 本发明具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液对二型糖尿病Table 2 The present invention has hypoglycemic, lipid-lowering and alleviating diabetic complication Litchi Kernel Health Care Oral Liquid to Type 2 Diabetes

大鼠血糖、胰岛等指标的影响表Effect table of rat blood sugar, islets and other indicators

注：不同字母代表二组间具有显著性差异，p<0.05。Note: Different letters represent significant differences between the two groups, p<0.05.

该表中模型组同正常组相比，高血糖、高血脂、胰岛素抵抗指数增加四项指标同样符合糖尿病症状。高、中、低三剂量组同模型组相比，在改善糖尿病大鼠胰岛素抵抗方面有显著作用，该特性与阳性药物消渴丸作用相当，且略优于阳性药。给药组对大鼠胰岛素抵抗能力的改善，也是其对二型糖尿病调节的关键所在。同时，高剂量组对糖尿病大鼠的空腹血糖值也有明显的降低作用。在总胆固醇和甘油三脂方面，其疗效也略优于消渴丸组。In the table, compared with the normal group, the four indicators of hyperglycemia, hyperlipidemia and insulin resistance index in the model group are also in line with the symptoms of diabetes. Compared with the model group, the high, medium and low dose groups have a significant effect on improving insulin resistance in diabetic rats, which is equivalent to the effect of the positive drug Xiaoke Pill, and slightly better than the positive drug. The improvement of insulin resistance in the administration group is also the key to its regulation of type 2 diabetes. At the same time, the high-dose group also had a significant effect on reducing the fasting blood glucose level of diabetic rats. In terms of total cholesterol and triglyceride, its curative effect was also slightly better than that of the Xiaoke Pill group.

综上，本发明可能通过改善胰岛素抵抗来达到降血糖、降血脂，缓解并改善糖尿病大鼠的并发症等症状，该饮品具有降糖、调脂及缓解糖尿病并发症的功效。To sum up, the present invention may lower blood sugar and blood fat by improving insulin resistance, alleviate and improve symptoms such as complications of diabetic rats, and the drink has the effects of lowering blood sugar, lowering fat and alleviating diabetic complications.

Claims (3)

1.一种具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液，其特征在于：其组成成分及重量份数如下：1. a health-care oral liquid of lychee core with hypoglycemic, fat-regulating and alleviating diabetic complications, is characterized in that: its composition and parts by weight are as follows: 所述的具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液的制备方法，步骤如下：The preparation method of the described Litchi Kernel Health Care Oral Liquid with hypoglycemic, fat-regulating and alleviating diabetic complications, the steps are as follows: 将荔枝核洗净，原料破碎后，以5～8倍重量的30～95％乙醇为溶媒，回流提取1～6次，每次2小时，过100～200目筛，将获得的荔枝核提取液用3500～5000转/min的转速离心，离心15～30min后，过滤得上清，上清回收乙醇，将提取液浓缩至65℃时相对密度为1.10-1.20，加乙醇使含醇量的体积百分比达65-85％，搅拌，静置，过滤，得荔枝核醇沉物，离心除沉淀，离心条件为转速3500-5000转/min、离心15～30min，过滤后得上清液，上清液回收乙醇，将提取液浓缩至相对密度为1.20-1.30，即得荔枝核醇提液，再依次加入山梨酸、食盐、木糖醇、甜菊糖，混合，加水，水的加入量为使其终体积为原料荔枝核重量的40-50倍，充分溶解后加入至调配罐中，搅拌器充分调配混匀后过滤、灌装、封口、杀菌处理，即得具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液。Wash the lychee core, after the raw material is crushed, use 5-8 times the weight of 30-95% ethanol as a solvent, reflux extraction 1-6 times, each time for 2 hours, pass through a 100-200 mesh sieve, and extract the obtained lychee core The solution is centrifuged at a speed of 3500-5000 rpm, centrifuged for 15-30min, then filtered to obtain the supernatant, and the supernatant is recovered with ethanol, and the relative density is 1.10-1.20 when the extract is concentrated to 65°C, and ethanol is added to make the alcohol content The volume percentage reaches 65-85%, stir, stand still, and filter to obtain the litchi kernel ethanol precipitate, centrifuge to remove the precipitate, and the centrifugation conditions are 3500-5000 rpm, centrifuge for 15-30min, and obtain the supernatant after filtration. Ethanol is recovered from the clear liquid, and the extract is concentrated to a relative density of 1.20-1.30 to obtain the lychee kernel ethanol extract, and then sorbic acid, salt, xylitol, and stevioside are added in sequence, mixed, and water is added in an amount of Its final volume is 40-50 times of the weight of the raw material lychee core, fully dissolved and added to the blending tank, fully blended and mixed by the agitator, filtered, filled, sealed, and sterilized to obtain the effect of lowering blood sugar, regulating fat and reducing blood sugar. Lychee Kernel Health Oral Liquid for Diabetic Complications. 2.根据权利要求1所述的具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液，其特征在于：其组成成分及重量份数如下：2. the lychee core health-care oral liquid with hypoglycemic, fat-regulating and alleviating diabetic complications according to claim 1, characterized in that: its composition and parts by weight are as follows: 3.根据权利要求1或2所述的具有降糖、调脂及缓解糖尿病并发症的荔枝核保健口服液，其特征在于：搅拌器充分调配混匀后过滤，用罐装机注入瓶中并自动封口，经过杀菌釜0.075～0.1MPa、20～30min杀菌后，冷却至62-68℃，即得到成品荔枝核口服液。3. according to claim 1 or 2, the litchi core health-care oral liquid with hypoglycemic, lipid-lowering and alleviating diabetic complications is characterized in that: the agitator is fully mixed and filtered, injected into the bottle with a canning machine and Automatic sealing, after being sterilized in a 0.075-0.1MPa autoclave for 20-30 minutes, cooled to 62-68°C, the finished litchi core oral liquid can be obtained.

CN201510452519.8A 2015-07-28 2015-07-28 A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication Active CN105030984B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510452519.8A CN105030984B (en) 2015-07-28 2015-07-28 A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510452519.8A CN105030984B (en) 2015-07-28 2015-07-28 A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication

Publications (2)

Publication Number Publication Date
CN105030984A CN105030984A (en) 2015-11-11
CN105030984B true CN105030984B (en) 2018-12-04

Family

ID=54438347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510452519.8A Active CN105030984B (en) 2015-07-28 2015-07-28 A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication

Country Status (1)

Country Link
CN (1) CN105030984B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105943681A (en) * 2016-04-28 2016-09-21 广州市中医医院 Semen litchi steroid saponin extract having function of improving insulin resistance
CN107389847B (en) * 2017-06-05 2020-01-07 中国农业科学院蜜蜂研究所 A method for rapid analysis of lipid components in bee pollen
CN109090402A (en) * 2018-06-28 2018-12-28 广西秀美壮乡能源环保有限公司 A kind of health drink and its processing method containing lichee bark extract
CN109090403A (en) * 2018-06-28 2018-12-28 广西秀美壮乡能源环保有限公司 A kind of health drink and its processing method containing Semen Litchi extract
CN110638896A (en) * 2019-09-09 2020-01-03 天津科技大学 Application and preparation method of litchi seed extract with blood pressure lowering and improvement of complications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985248A (en) * 1987-06-18 1991-01-15 Yaguang Liu Pharmaceutical composition containing a safe extracts of fruits and vegetables for the treating and preventing of diabetes
CN1879743A (en) * 2006-04-29 2006-12-20 岭南荔枝加工工程技术惠州研究中心 Oral liquid of litchi seed and method for making same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985248A (en) * 1987-06-18 1991-01-15 Yaguang Liu Pharmaceutical composition containing a safe extracts of fruits and vegetables for the treating and preventing of diabetes
CN1879743A (en) * 2006-04-29 2006-12-20 岭南荔枝加工工程技术惠州研究中心 Oral liquid of litchi seed and method for making same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
荔枝核降血糖、调血脂和抗氧化的实验研究;潘竞锵等;《广东药学》;19991231;第9卷(第1期);第47-50页 *

Also Published As

Publication number Publication date
CN105030984A (en) 2015-11-11

Similar Documents

Publication Publication Date Title
CN105030984B (en) 2018-12-04 A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication
CN106975012B (en) 2020-03-17 Traditional Chinese medicine composition for reducing blood sugar and preparation method thereof
CN103070880B (en) 2014-07-16 Application of acanthopanax trifoliatus polysaccharide in preparing medicine for treating diabetes
CN107412341A (en) 2017-12-01 A kind of hypoglycemic formula containing blue or green money willow and preparation method thereof
CN104431064B (en) 2018-03-13 A kind of blood-sugar reducing tea and preparation method thereof
CN1840166A (en) 2006-10-04 Modern Chinese medicinal oral liquid of &#39;Wen Dan Tang&#39; and preparation method thereof
CN102688295A (en) 2012-09-26 Chinese medicine composition for controlling metabolic diseases as well as preparation method and application thereof
CN108578544A (en) 2018-09-28 A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function
CN103181560B (en) 2015-06-17 Health food having effects of life cultivation and health preservation in winter and preparation method thereof
CN109985086A (en) 2019-07-09 Green money willow leaf instant powder and preparation method thereof
CN103637179A (en) 2014-03-19 Food composition with functions of lowering blood sugar and blood fat and improving fatty liver
EP1369123A1 (en) 2003-12-10 A health-care product comprising lotus rhizome and process for its preparation
CN106727902B (en) 2020-09-11 Chinese medicinal composition for hangover and liver protection containing Cordyceps sinensis and its application
CN103463244A (en) 2013-12-25 Method for extracting blood sugar lowering substance from China roses and application of blood sugar lowering substance
CN104013696B (en) 2017-03-29 A kind of plant drug composition of preventing and treating metabolism syndrome and its application
CN113318139A (en) 2021-08-31 A Chinese medicinal composition used as both medicine and food for lowering blood sugar and reducing blood lipid
CN106421491A (en) 2017-02-22 Formula of radix helicteris oral liquid with blood glucose reducing effect and preparation method
CN116849357B (en) 2024-10-22 Medicinal and edible composition with liver protection function and preparation method thereof
CN105169187B (en) 2018-10-30 A kind of composition and its application, preparation method and drug, food containing the composition
CN110179855A (en) 2019-08-30 A kind of therapeutic agent and its formulation preparation method of post-natal depression
CN104225185B (en) 2017-09-29 A kind of hypoglycemic chewing gum and its production method
CN104740345B (en) 2018-03-13 Treat Chinese medicine composition of diabetes and preparation method thereof
CN116920061B (en) 2024-05-17 Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof
CN103800449B (en) 2016-04-27 A kind of Chinese medicine composition for the treatment of Yin Xu Nei Re Zheng type 2 diabetes mellitus
CN103301380A (en) 2013-09-18 Liver-soothing and qi-regulating traditional Chinese medicinal composition and preparation method thereof

Legal Events

Date Code Title Description
2015-11-11 C06 Publication
2015-11-11 PB01 Publication
2016-01-13 C10 Entry into substantive examination
2016-01-13 SE01 Entry into force of request for substantive examination
2018-12-04 GR01 Patent grant
2018-12-04 GR01 Patent grant
2024-07-19 TR01 Transfer of patent right
2024-07-19 TR01 Transfer of patent right

Effective date of registration: 20240703

Address after: Room 2-2228, Fashion ONE Apartment, No.1 Kaiyuan Avenue, Luolong District, Luoyang City, Henan Province, China 471026

Patentee after: Zhongzhi Yunchuang (Henan) Information Technology Co.,Ltd.

Country or region after: China

Address before: 300222 Tianjin University of Science and Technology, 1038 South Road, Tianjin, Hexi District, Dagu

Patentee before: TIANJIN University OF SCIENCE AND TECHNOLOGY

Country or region before: China

2024-12-20 TR01 Transfer of patent right
2024-12-20 TR01 Transfer of patent right

Effective date of registration: 20241203

Address after: 276000 West side of the intersection of Provincial Highway 230 and Hengchang Avenue in Qiaotou Village, Chudun Town, Luozhuang District, Linyi City, Shandong Province

Patentee after: Shandong Gaoguan Food Co.,Ltd.

Country or region after: China

Address before: Room 2-2228, Fashion ONE Apartment, No.1 Kaiyuan Avenue, Luolong District, Luoyang City, Henan Province, China 471026

Patentee before: Zhongzhi Yunchuang (Henan) Information Technology Co.,Ltd.

Country or region before: China